Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke

Authors: Raquel Rodríguez-González, Tomás Sobrino, Manuel Rodríguez-Yáñez, Mónica Millán, David Brea, Elena Miranda, Octavio Moldes, Juan Pérez, David A Lomas, Rogelio Leira, Antoni Dávalos, José Castillo

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

Neuroserpin has shown neuroprotective effects in animal models of cerebral ischemia and has been associated with functional outcome after ischemic stroke. Our aim was to study whether neuroserpin serum levels could be associated to biomarkers of excitotoxicity, inflammation and blood brain barrier disruption.

Methods

We prospectively included 129 patients with ischemic stroke (58.1% male; mean age, 72.4 ± 9.6 years) not treated with tPA within 12 hours (h) of symptoms onset (mean time, 4.7 ± 2.1 h). Poor functional outcome at 3 months was considered as a modified Rankin scale score >2. Serum levels of neuroserpin, Interleukin 6 (IL-6), Intercellular adhesion molecule-1 (ICAM-1), active Matrix metalloproteinase 9 (MMP-9), and cellular fibronectin (cFn) (determined by ELISA) and glutamate (determined by HPLC) were measured on admission, 24 and 72 h. The main variable was considered the decrease of neuroserpin levels within the first 24 h. ROC analysis was used to select the best predictive value for neuroserpin to predict poor functional outcome due to a lack of linearity.

Results

The decrease of neuroserpin levels within the first 24 h was negatively correlated with serum levels at 24 hours of glutamate (r = -0.642), IL-6 (r = -0.678), ICAM-1 (r = -0.345), MMP-9 (r = -0.554) and cFn (r = -0.703) (all P < 0.0001). In the multivariate analysis, serum levels of glutamate (OR, 1.04; CI95%, 1.01-1.06, p = 0.001); IL-6 (OR, 1.4; CI95%, 1.1-1.7, p = 0.001); and cFn (OR, 1.3; CI95%, 1.1-1.6, p = 0.002) were independently associated with a decrease of neuroserpin levels <70 ng/mL at 24 h after adjusting for confounding factors.

Conclusions

These findings suggest that neuroprotective properties of neuroserpin may be related to the inhibition of excitotoxicity, inflammation, as well as blood brain barrier disruption that occur after acute ischemic stroke.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rogove AD, Siao C, Keyt B, Strickland S, Tsirka SE: Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci. 1999, 112: 4007-4016.PubMed Rogove AD, Siao C, Keyt B, Strickland S, Tsirka SE: Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci. 1999, 112: 4007-4016.PubMed
2.
go back to reference Melchor JP, Strickland S: Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost. 2005, 93: 655-660.PubMedCentralPubMed Melchor JP, Strickland S: Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost. 2005, 93: 655-660.PubMedCentralPubMed
3.
go back to reference Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN, Osterwalder T, Rulicke T, Sonderegger P: Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci. 2001, 18: 443-457.CrossRefPubMed Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN, Osterwalder T, Rulicke T, Sonderegger P: Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci. 2001, 18: 443-457.CrossRefPubMed
4.
go back to reference Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA: Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood. 2000, 96: 569-576.PubMed Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA: Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood. 2000, 96: 569-576.PubMed
5.
go back to reference Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M: Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation. 2002, 106: 740-745.CrossRefPubMed Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M: Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation. 2002, 106: 740-745.CrossRefPubMed
6.
go back to reference Rodríguez-González R, Millán M, Sobrino T, Miranda E, Brea D, Pérez de la Ossa N, Blanco M, Pérez J, Dorado L, Castellanos M, Lomas DA, Moro MA, Dávalos A, Castillo J: The natural tissue plasminogen activator inhibitor neuroserpin and acute ischemic stroke outcome. Thromb Haemost. 2011, 105: 421-429.CrossRefPubMed Rodríguez-González R, Millán M, Sobrino T, Miranda E, Brea D, Pérez de la Ossa N, Blanco M, Pérez J, Dorado L, Castellanos M, Lomas DA, Moro MA, Dávalos A, Castillo J: The natural tissue plasminogen activator inhibitor neuroserpin and acute ischemic stroke outcome. Thromb Haemost. 2011, 105: 421-429.CrossRefPubMed
7.
go back to reference European Stroke Organisation (ESO) Executive Committee: ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008, 25: 457-507.CrossRef European Stroke Organisation (ESO) Executive Committee: ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008, 25: 457-507.CrossRef
8.
go back to reference Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke. 1993, 24: 35-41.CrossRefPubMed Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke. 1993, 24: 35-41.CrossRefPubMed
9.
go back to reference Miranda E, MacLeod I, Davies MJ, Perez J, Romisch K, Crowther DC, Lomas DA: The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet. 2008, 17: 1527-1539.PubMedCentralCrossRefPubMed Miranda E, MacLeod I, Davies MJ, Perez J, Romisch K, Crowther DC, Lomas DA: The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet. 2008, 17: 1527-1539.PubMedCentralCrossRefPubMed
10.
go back to reference Miranda E, Romisch K, Lomas DA: Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem. 2004, 279: 28283-28291.CrossRefPubMed Miranda E, Romisch K, Lomas DA: Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem. 2004, 279: 28283-28291.CrossRefPubMed
11.
go back to reference Castillo J, Davalos A, Naveiro J, Noya M: Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke. 1996, 27: 1060-1065.CrossRefPubMed Castillo J, Davalos A, Naveiro J, Noya M: Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke. 1996, 27: 1060-1065.CrossRefPubMed
12.
go back to reference Castillo J, Davalos A, Noya M: Progression of ischaemic stroke and excitotoxic aminoacids. Lancet. 1997, 349: 79-83.CrossRefPubMed Castillo J, Davalos A, Noya M: Progression of ischaemic stroke and excitotoxic aminoacids. Lancet. 1997, 349: 79-83.CrossRefPubMed
13.
go back to reference Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, Tarkowski A: Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol. 1997, 110: 492-499.PubMedCentralCrossRefPubMed Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, Tarkowski A: Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol. 1997, 110: 492-499.PubMedCentralCrossRefPubMed
14.
go back to reference Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000, 31: 2325-2329.CrossRefPubMed Vila N, Castillo J, Davalos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000, 31: 2325-2329.CrossRefPubMed
15.
go back to reference Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003, 107: 598-603.CrossRefPubMed Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003, 107: 598-603.CrossRefPubMed
16.
go back to reference Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A: Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004, 35: 1671-1676.CrossRefPubMed Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Davalos A: Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004, 35: 1671-1676.CrossRefPubMed
17.
go back to reference Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Davalos A: The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke. 2005, 36: 1921-1926.CrossRefPubMed Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Davalos A: The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke. 2005, 36: 1921-1926.CrossRefPubMed
18.
go back to reference Castellanos M, Sobrino T, Millan M, Garcia M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Castillo J, Davalos A: Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study. Stroke. 2007, 38: 1855-1859.CrossRefPubMed Castellanos M, Sobrino T, Millan M, Garcia M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Castillo J, Davalos A: Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study. Stroke. 2007, 38: 1855-1859.CrossRefPubMed
19.
go back to reference Castellanos M, Serena J: Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis. 2007, 24 (Suppl 1): 7-15.CrossRefPubMed Castellanos M, Serena J: Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis. 2007, 24 (Suppl 1): 7-15.CrossRefPubMed
20.
go back to reference Castellanos M, Castillo J, Davalos A: Laboratory studies in the investigation of stroke. Handb Clin Neurol. 2008, 94: 1081-1095.CrossRef Castellanos M, Castillo J, Davalos A: Laboratory studies in the investigation of stroke. Handb Clin Neurol. 2008, 94: 1081-1095.CrossRef
21.
go back to reference Zhao G, Reynolds JN, Flavin MP: Temporal profile of tissue plasminogen activator (tpa) and inhibitor expression after transient focal cerebral ischemia. Neuroreport. 2003, 14: 1689-1692.CrossRefPubMed Zhao G, Reynolds JN, Flavin MP: Temporal profile of tissue plasminogen activator (tpa) and inhibitor expression after transient focal cerebral ischemia. Neuroreport. 2003, 14: 1689-1692.CrossRefPubMed
22.
go back to reference Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001, 7: 59-64.CrossRefPubMed Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001, 7: 59-64.CrossRefPubMed
23.
go back to reference Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, Rossier J, Jarrige AC, Mackenzie ET, Colloc'h N, Ali C, Vivien D: Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of n-methyl-d-aspartate receptor signaling. J Biol Chem. 2004, 279: 50850-50856.CrossRefPubMed Fernandez-Monreal M, Lopez-Atalaya JP, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, Rossier J, Jarrige AC, Mackenzie ET, Colloc'h N, Ali C, Vivien D: Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of n-methyl-d-aspartate receptor signaling. J Biol Chem. 2004, 279: 50850-50856.CrossRefPubMed
24.
go back to reference Lebeurrier N, Liot G, Lopez-Atalaya JP, Orset C, Fernandez-Monreal M, Sonderegger P, Ali C, Vivien D: The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol Cell Neurosci. 2005, 30: 552-558.CrossRefPubMed Lebeurrier N, Liot G, Lopez-Atalaya JP, Orset C, Fernandez-Monreal M, Sonderegger P, Ali C, Vivien D: The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol Cell Neurosci. 2005, 30: 552-558.CrossRefPubMed
25.
go back to reference Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A: Inflammation-mediated damage in progressing lacunar infarctions: A potential therapeutic target. Stroke. 2002, 33: 982-987.CrossRefPubMed Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Davalos A: Inflammation-mediated damage in progressing lacunar infarctions: A potential therapeutic target. Stroke. 2002, 33: 982-987.CrossRefPubMed
26.
go back to reference Siao CJ, Fernandez SR, Tsirka SE: Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci. 2003, 23: 3234-3242.PubMed Siao CJ, Fernandez SR, Tsirka SE: Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci. 2003, 23: 3234-3242.PubMed
27.
go back to reference Flavin MP, Zhao G, Ho LT: Microglial tissue plasminogen activator (tpa) triggers neuronal apoptosis in vitro. Glia. 2000, 29: 347-354.CrossRefPubMed Flavin MP, Zhao G, Ho LT: Microglial tissue plasminogen activator (tpa) triggers neuronal apoptosis in vitro. Glia. 2000, 29: 347-354.CrossRefPubMed
28.
go back to reference Meager A: Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev. 1999, 10: 27-39.CrossRefPubMed Meager A: Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev. 1999, 10: 27-39.CrossRefPubMed
29.
go back to reference Milner R, Campbell IL: The extracellular matrix and cytokines regulate microglial integrin expression and activation. J Immunol. 2003, 170: 3850-3858.CrossRefPubMed Milner R, Campbell IL: The extracellular matrix and cytokines regulate microglial integrin expression and activation. J Immunol. 2003, 170: 3850-3858.CrossRefPubMed
30.
go back to reference del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, Koziol JA: Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke. 2007, 38: 646-651.CrossRefPubMed del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, Koziol JA: Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke. 2007, 38: 646-651.CrossRefPubMed
31.
go back to reference Summers L, Kielty C, Pinteaux E: Adhesion to fibronectin regulates interleukin-1 beta expression in microglial cells. Mol Cell Neurosci. 2009, 41: 148-155.CrossRefPubMed Summers L, Kielty C, Pinteaux E: Adhesion to fibronectin regulates interleukin-1 beta expression in microglial cells. Mol Cell Neurosci. 2009, 41: 148-155.CrossRefPubMed
32.
go back to reference Opdenakker G, Van den Steen PE, Van Damme J: Gelatinase b: A tuner and amplifier of immune functions. Trends Immunol. 2001, 22: 571-579.CrossRefPubMed Opdenakker G, Van den Steen PE, Van Damme J: Gelatinase b: A tuner and amplifier of immune functions. Trends Immunol. 2001, 22: 571-579.CrossRefPubMed
33.
go back to reference Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR: Increased gelatinase a (mmp-2) and gelatinase b (mmp-9) activities in human brain after focal ischemia. Neurosci Lett. 1997, 238: 53-56.CrossRefPubMed Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR: Increased gelatinase a (mmp-2) and gelatinase b (mmp-9) activities in human brain after focal ischemia. Neurosci Lett. 1997, 238: 53-56.CrossRefPubMed
34.
go back to reference Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. 1999, 19: 624-633.CrossRefPubMed Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab. 1999, 19: 624-633.CrossRefPubMed
35.
go back to reference Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998, 29: 1020-1030.CrossRefPubMed Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998, 29: 1020-1030.CrossRefPubMed
36.
go back to reference Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003, 34: 40-46.CrossRefPubMed Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003, 34: 40-46.CrossRefPubMed
37.
go back to reference Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003, 9: 1313-1317.CrossRefPubMed Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med. 2003, 9: 1313-1317.CrossRefPubMed
38.
go back to reference Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J, Lo EH: Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005, 36: 1954-1959.CrossRefPubMed Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J, Lo EH: Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005, 36: 1954-1959.CrossRefPubMed
39.
go back to reference Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ: Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006, 66: 1550-1555.CrossRefPubMed Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ: Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006, 66: 1550-1555.CrossRefPubMed
40.
go back to reference Rodríguez-González R, Agulla J, Sobrino T, Castillo J: Neuroprotective effect of neuroserpin in rat primary cortical cultures after oxygen and glucose deprivation and tPA. Neurochem Int. 2011, 58: 337-343.CrossRefPubMed Rodríguez-González R, Agulla J, Sobrino T, Castillo J: Neuroprotective effect of neuroserpin in rat primary cortical cultures after oxygen and glucose deprivation and tPA. Neurochem Int. 2011, 58: 337-343.CrossRefPubMed
Metadata
Title
Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke
Authors
Raquel Rodríguez-González
Tomás Sobrino
Manuel Rodríguez-Yáñez
Mónica Millán
David Brea
Elena Miranda
Octavio Moldes
Juan Pérez
David A Lomas
Rogelio Leira
Antoni Dávalos
José Castillo
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-58

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.